CapitalCubeStemline Therapeutics, Inc. reports financial results for the quarter ended June 30, 2017.
We analyze the earnings along side the following peers of Stemline Therapeutics, Inc. – Celgene Corporation, Cyclacel Pharmaceuticals, Inc., Agenus Inc., Verastem, Inc., Sunesis Pharmaceuticals, Inc., OncoMed Pharmaceuticals, Inc., Pfizer Inc., Johnson & Johnson and ImmunoCellular Therapeutics, Ltd. (CELG-US, CYCC-US, AGEN-US, VSTM-US, SNSS-US, OMED-US, PFE-US, JNJ-US and IMUC-US) that have also reported for this period.
Highlights
- Summary numbers: Revenues of USD 0.30 million, Net Earnings of USD -15.46 million.
- Year-on-year change in operating cash flow of -91.53% is about the same as the change in earnings, likely no significant movement in accruals or reserves.
- Narrowing of operating margins contributed to decline in earnings.
The table below shows the preliminary results and recent trends for key metrics such as revenues and net income growth:
| 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | |
|---|---|---|---|---|---|
| Relevant Numbers (Quarterly) | |||||
| Revenues (mil) | 0.3 | 0.3 | 0.3 | 0.3 | 0.24 |
| Revenue Growth (%YOY) | 26.38 | 0 | 45.59 | 45.59 | 95.09 |
| Earnings (mil) | -15.46 | -14.57 | -10.01 | -9.92 | -9.32 |
| Earnings Growth (%YOY) | -65.81 | -60.98 | 1.68 | -7.47 | 8.19 |
| Net Margin (%) | -5162.62 | -4865.05 | -3343.04 | -3314.36 | -3935.04 |
| EPS | -0.66 | -0.67 | -0.56 | -0.56 | -0.52 |
| Return on Equity (%) | -17.85 | -19.3 | -16.21 | -14.3 | -12.14 |
| Return on Assets (%) | -61.67 | -66.72 | -55.92 | -50.47 | -43.42 |
Access our Ratings and Scores for Stemline Therapeutics, Inc.
Market Share Versus Profits
STML-US‘s change in revenue this period compared to the same period last year of 26.38% is almost the same as its change in earnings, and is about average among the announced results thus far in its peer group, suggesting that STML-US is holding onto its market share. Also, for comparison purposes, revenues changed by 0% and earnings by -6.12% compared to the immediate last period.
Quadrant label definitions. Hover to know more
Cash Versus Earnings – Sustainable Performance?
It is important to examine a company�s cash versus earnings numbers to gauge whether its performance is sustainable.
STML-US‘s change in operating cash flow of -91.53% compared to the same period last year is about the same as its change in earnings this period. Additionally, this change in operating cash flow is about average among its peer group. This suggests that the company did not use accruals or reserves to manage earnings this period, and that, all else being equal, the earnings number is sustainable.
Quadrant label definitions. Hover to know more
Margins
The company’s decline in earnings has been influenced by the following factors: (1) Decline in operating margins (EBIT margins) from -4,009.99% to -5,230.53% and (2) one-time items that contributed to a decrease in pretax margins from -3,946.33% to -5,162.62%
Quadrant label definitions. Hover to know more
Access our Ratings and Scores for Stemline Therapeutics, Inc.
Company Profile
Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. It develops a discovery platform called StemScreen, which identifies novel compounds that target and kill cancer stem cells. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.
CapitalCube does not own any shares in the stocks mentioned and focuses solely on providing unique fundamental research and analysis on approximately 50,000 stocks and ETFs globally. Try any of our analysis, screener or portfolio premium services free for 7 days. To get a quick preview of our services, check out our free quick summary analysis of STML-US.